PF-06463922, an ALK/ROS1 inhibitor, overcomes resistance to 1(st) and 2(nd) generation ALK inhibitors in pre-clinical models

We report the preclinical evaluation of PF-06463922, a potent and brain penetrant ALK/ROS1 inhibitor. Compared to other clinically available ALK inhibitors, PF-06463922 displayed superior potency against all known clinically acquired ALK mutations, including the highly resistant G1202R mutant. Furth...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Cancer Cell
Main Authors: Zou, Helen Y., Friboulet, Luc, Kodack, David P., Engstrom, Lars D., Li, Qiuhua, West, Melissa, Tang, Ruth W., Wang, Hui, Tsaparikos, Konstantinos, Wang, Jinwei, Timofeevski, Sergei, Katayama, Ryohei, Dinh, Dac M., Lam, Hieu, Lam, Justine L., Yamazaki, Shinji, Hu, Wenyue, Patel, Bhushankumar, Bezwada, Divya, Frias, Rosa L., Lifshits, Eugene, Mahmood, Sidra, Gainor, Justin F., Affolter, Timothy, Lappin, Patrick B., Gukasyan, Hovhannes, Lee, Nathan, Deng, Shibing, Jain, Rakesh K, Johnson, Ted W., Shaw, Alice T., Fantin, Valeria R., Smeal, Tod
Format: Artigo
Sprog:Inglês
Udgivet: 2015
Fag:
Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4504786/
https://ncbi.nlm.nih.gov/pubmed/26144315
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ccell.2015.05.010
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker